MRE11 and neoplasm: Administration of CBP or LDH inhibitors, or cell-penetrating peptides that can specifically block the lactylation of MRE11, can reduce the lactylation of MRE11, inhibit HR, and enhance the sensitivity of tumor cells to chemotherapeutic agents such as cisplatin, PARPi, etc [26].